Fulcrum Therapeutics (FULC) Income from Continuing Operations (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Income from Continuing Operations of 34984000.0 for Q2 2026, up 16.65% year-over-year from 29991165.68 in Q2 2025, and up 29.98% quarter-over-quarter from 49965473.0 in Q1 2026.
Fulcrum Therapeutics (FULC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Income from Continuing Operations for 9 consecutive years, with 34984000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 16.65% year-over-year to 34984000.0; the TTM figure through Jun 2026 stood at 234095687.0 (down 78.59% YoY), while the FY2025 annual figure was 161231000.0, down 119.71% from the prior year.
- Income from Continuing Operations grew to 34984000.0 in Q2 2026 per FULC's latest filing, from 49965473.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 40216583.0 in Q2 2024 and bottomed at 93996741.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 42797378.61 across 5 years, with a median of 41579000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 197.39% — and 2025, when it slumped 236.18%.
- Fulcrum Therapeutics' Income from Continuing Operations stood at 29858160.0 in 2022, then slumped by 44.37% to 43106074.0 in 2023, then soared by 41.93% to 25031463.0 in 2024, then plunged by 236.18% to 84151718.0 in 2025, then soared by 58.43% to 34984000.0 in 2026.
- Business Quant data shows FULC's Income from Continuing Operations at 34984000.0 in Q2 2026, 49965473.0 in Q1 2026, and 84151718.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -34.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.98 Mn |
| Mar 31, 2026 | -49.97 Mn |
| Dec 31, 2025 | -84.15 Mn |
| Sep 30, 2025 | -64.99 Mn |
| Jun 30, 2025 | -41.97 Mn |
| Mar 31, 2025 | -29.43 Mn |
| Dec 31, 2024 | -25.03 Mn |
| Sep 30, 2024 | -25.68 Mn |
| Jun 30, 2024 | 40.22 Mn |
| Mar 31, 2024 | -65.24 Mn |
| Dec 31, 2023 | -43.11 Mn |
| Sep 30, 2023 | -40.26 Mn |
| Jun 30, 2023 | -30.65 Mn |
| Mar 31, 2023 | -30.52 Mn |
| Dec 31, 2022 | -192.46 Mn |
| Sep 30, 2022 | -27.08 Mn |
| Jun 30, 2022 | -35.44 Mn |
| Mar 31, 2022 | -94.00 Mn |
| Dec 31, 2021 | -50.95 Mn |
| Sep 30, 2021 | -96.47 Mn |